Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia
Abstract
PURPOSE Patients undergoing hematopoietic stem-cell transplantation (HSCT) or induction chemotherapy for acute leukemia (AL) generally receive a low-bacterial neutropenic diet (ND) to minimize infection from ingested microbes. Recent studies suggest that a more liberalized diet (LD) might be safe. However, those studies lacked robust designs to demonstrate noninferiority and did not address whether an LD improves caloric intake or nutritional status. This trial aimed to determine whether the rate of major infections in LD patients was noninferior to that in ND patients and whether an LD improved caloric intake and nutritional status. METHODS In this phase III noninferiority trial, patients were randomly assigned to either an ND or LD, containing fresh fruits and vegetables. The primary end point was the development of any major infection during neutropenia. The noninferiority margin was set at a difference of ≤10% in the major infection rate. RESULTS The trial was halted at the second interim analysis after enrolling 214 evaluable patients, because of the LD arm's major infection rate surpassing the predefined stopping boundary. In the LD arm, major infections occurred in 31.4% of patients compared with 20.2% of patients in the ND arm, a difference of 11.2% ([95% CI, –0.4 to 22.9]; P = .58). Furthermore, the caloric intake in the LD arm was not improved and nearly two thirds of patients on both diets reported critical nutritional problems. There was no advantage in symptoms, quality of life, or survival for the LD arm. CONCLUSION These findings suggest that LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit. Further dietary strategies are needed to improve nutrition without compromising safety.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (18)
John R. Wingard
5Department of Medicine, University of Florida, Gainesville, FL
Ji-Hyun Lee
Derek Li
John R. Wingard, MD, Ji-Hyun Lee, DrPH, and Derek Li, MS, University of Florida, Gainesville, FL
Zeina Al-Mansour
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL
Nosha Farhadfar
6Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, United States
Jack Hsu
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL
John Hiemenz
6University of Florida, Gainsville, United States
Erin A. Dean
Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA
Randy Brown
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL
Gaurav Trikha
Cancer Specialists of North Florida, Jacksonville, FL
Jenna N. Schulz
University of Florida Health, Food and Nutrition, Gainesville, FL
Christina L. Cline
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL
Helen Leather
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL
Michele W. Sugrue
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL
Wendy J. Dahl
Department of Food Science and Human Nutrition, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL
Kristina H. McGee
University of Florida Health, Food and Nutrition, Gainesville, FL
Alex Leggett
Clinical Research Office, University of Florida Health Cancer Center, Gainesville, FL
Debra Lynch Kelly
College of Nursing, University of Florida, Gainesville, FL